Integral Health Asset Management, LLC Krystal Biotech, Inc. Transaction History

Integral Health Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $765,600 - $918,199	5,000 Added 6.25%	85,000 $15.6 Million
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $540,050 - $896,750	-5,000 Reduced 5.88%	80,000 $14.2 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $1.44 Million - $1.92 Million	15,000 Added 21.43%	85,000 $10.5 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $868,080 - $1.04 Million	8,000 Added 12.9%	70,000 $8.12 Million
Q2 2023 Aug 11, 2023	SELL	$78.48 - $130.32 $1.81 Million - $3 Million	-23,000 Reduced 27.06%	62,000 $7.28 Million
Q1 2023 May 09, 2023	SELL	$72.39 - $84.27 $2.17 Million - $2.53 Million	-30,000 Reduced 26.09%	85,000 $6.81 Million
Q4 2022 Feb 13, 2023	BUY	$63.14 - $79.9 $1.58 Million - $2 Million	25,000 Added 27.78%	115,000 $9.11 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $2.45 Million - $3.12 Million	37,816 Added 72.47%	90,000 $6.27 Million
Q2 2022 Aug 03, 2022	BUY	$48.93 - $73.47 $2.55 Million - $3.83 Million	52,184 New	52,184 $3.43 Million

309

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.06B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.